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Abstract
Background: Understanding the geographical distribution of drug resistance of Plasmodium falciparum is
important for the effective treatment of malaria. Drug resistance has previously been inferred mainly from records
of clinical resistance. However, clinical resistance is not always consistent with the parasite’s genetic resistance.
Thus, molecular identification of the parasite’s drug resistance is required. In Africa, clinical resistance to
pyrimethamine (Pyr) and chloroquine (CQ) was evident before 1980 but few studies investigating the genetic
resistance to these drugs were conducted before the late 1990s. In this study, genotyping of genes involved in
resistance to Pyr and CQ was performed using archive blood samples from Africa between 1984 and 1998.
Methods: Parasite DNA was extracted from P. falciparum-infected blood smears collected from travellers returning
to Japan from Africa between 1984 and 1998. Genotypes of the dihydrofolate reductase gene (dhfr) and CQ-
resistance transporter gene (pfcrt) were determined by polymerase chain reaction amplification and sequencing.
Results: Genotyping of dhfr and pfcrt was successful in 59 and 80 samples, respectively. One wild-type and seven
mutant dhfr genotypes were identified. Three dhfr genotypes lacking the S108N mutation (NRSI, ICSI, IRSI; amino
acids at positions 51, 59, 108, and 164 with mutations underlined) were highly prevalent before 1994 but reduced
after 1995, accompanied by an increase in genotypes with the S108N mutation. The dhfr IRNI genotype was first
identified in Nigeria in 1991 in the present samples, and its frequency gradually increased. However, two double
mutants (ICNI and NRNI), the latter of which was exclusively found in West Africa, were more frequent than the
IRNI genotype. Only two pfcrt genotypes were found, the wild-type and a Southeast Asian type (CVIET; amino acids
at positions 72-76 with mutations underlined). The CVIET genotype was already present as early as 1984 in
Tanzania and Nigeria, and appeared throughout Africa between 1984 and 1998.
Conclusions: This study is the first to report the molecular identification of Pyr- and CQ-resistant genotypes of P.
falciparum in Africa before 1990. Genotyping of dhfr and pfcrt using archive samples has revealed new aspects of
the evolutionary history of Pyr- and CQ-resistant parasites in Africa.
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Background
Drug resistance of Plasmodium falciparum, the most
virulent human malaria parasite, is imposing a serious
problem for the effective treatment of malaria in almost
all endemic areas. Thus it is imperative to understand
the geographical distribution and origin of the parasite’s
drug resistance. In Africa, clinical resistance of falci-
parum malaria to chloroquine (CQ) was first reported in
the late 1970s [1,2]. In addition, while clinical resistance
to pyrimethamine (Pyr) had been reported in limited
endemic foci in the 1950s after mass drug treatment
using Pyr [3,4], highly resistant parasites became
remarkably frequent and spread into endemic regions
throughout Africa during the 1990s after the implemen-
tation of sulphadoxine/pyrimethamine (SP) as a first-line
therapy in these regions [5]. Clinical resistance is not
always consistent with genetic resistance because drug
resistance results from the interplay of the parasite,
drug, and human host, and is largely influenced by
immune factors. In highly endemic areas in Africa,
where individuals often possess semi-immunity against
malaria after repeated infections, this semi-immunity
more or less strengthens efficacy of anti-malarial drugs
to drug-resistant parasites [6,7]. Thus, in Africa the tim-
ing of the first appearance of genetic resistance to CQ
and Pyr and its subsequent spread in the continent
remain to be explored.
The P. falciparum chloroquine-resistance transporter
gene (pfcrt) was identified as a primary target gene for
CQ resistance in 2000 [8]. PfCRT is a transmembrane
protein, localized to the parasite’s food vacuole [9]. An
amino acid substitution at position 76 from lysine to
threonine (K76T) in pfcrt confers resistance to CQ [8].
Pyr inhibits a key enzyme in the folate biosynthetic path-
way, dihydrofolate reductase (DHFR), which is encoded
by the parasite dihydrofolate reductase gene (dhfr). Four
major amino acid substitutions in dhfr have been widely
recognised among Pyr-resistant parasites [10,11]. A
mutation at position 108 from serine to asparagine
(S108N), leading to the NCNI dhfr genotype (amino
acids at positions 51, 59, 108, and 164 with mutation
underlined), is essential for conferring a mild resistance
to Pyr in the parasite [10-13]. Additional point mutations
at 51, 59, and 164 are associated with increased levels of
Pyr resistance in vitro [11]. Importantly, as the number
of mutations in dhfr increases, levels of resistance to Pyr
become higher [13]. The IRNL dhfr genotype of the
quadruple mutant shows so far the highest IC50 values to
Pyr (1,111-fold as compared to that of the wild-type para-
site) [13]. The IRNL dhfr genotype is predominant in
Southeast Asia and South America where the efficacy of
SP has already reached unacceptable levels [14].
Recent molecular studies using microsatellite markers
showed that the geographical origins of the mutant pfcrt
genotypes were extremely restricted and resistant geno-
types spread into almost all endemic regions, due to a
selective sweep driven by treatment with CQ [14-17].
The CVIET (amino acids at positions 72-76 in pfcrt
with mutations underlined) genotype represents the
most common CQ-resistant type in Southeast Asia,
which expanded to Africa. Similarly, a highly Pyr-resis-
tant dhfr genotype (IRNI triple mutant) emerged from
Southeast Asia and migrated to Africa, where it spread
into endemic regions throughout Africa [14,18,19].
The identification of pfcrt and dhfr as target genes for
drug resistance provides solid ground for exploring the
geographical distribution and spread of CQ- and Pyr-
resistant P. falciparum. However, previous reports of
genetic resistance (but not clinical resistance) to these
drugs are very limited before the 1990s, since the target
genes for CQ- and Pyr-resistance were not identified
until 2000 and 1988, respectively [8,10,20]. Indeed, stu-
dies on the genotypes of drug-resistant genes are scarce,
with only one report each for pfcrt [21] and dhfr [22] in
the late 1980s in Africa. Investigating the geographical
distribution of pfcrt and dhfr genotypes in Africa before
1990 is undoubtedly crucial for tracing the evolutionary
history of CQ- and Pyr-resistance in the continent, where
both CQ- and Pyr-resistance was introduced from South-
east Asia. To address this issue, genotyping of archive
blood samples was performed using samples collected
from travellers who had returned from Africa between
1984 and 1998. Results show that in Africa the CQ-resis-
tant pfcrt genotype was already widely prevalent in the
1980s, and the highly Pyr-resistant dhfr genotypes (dou-
ble and triple mutants) increased after the mid-1990s.
Methods
Collection of samples and DNA extraction
The archive blood samples used in this study had been
collected and stored as blood smears for the national sur-
veillance system of imported malaria cases operating in
50 hospitals in Japan from 1984 to 1998 [23]. Of the 588
malaria cases imported to Japan during the period, 122
Plasmodium falciparum cases were derived from 23 Afri-
can countries. Parasite DNA was extracted from Giemsa-
stained thin blood smears as previously described [23].
Briefly, Giemsa-stained slides were dipped in xylene and
then in methanol to remove the immersion oil and dye,
respectively. Each blood smear was scraped off with the
edge of a clean glass slide, and subjected to DNA purifi-
cation using the QIAamp DNA Blood Mini Kit (Qiagen,
Hilden, Germany). A non-infected blood smear was also
used as a negative control in the DNA extraction and
polymerase chain reaction (PCR) amplification proce-
dures. In total, genotyping was successful for dhfr and/or
pfcrt in 85 samples of the 122 samples examined [see
Additional file 1].
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Molecular analysis
For genotyping of the dhfr locus, amplification of a 350-
base pair fragment covering the four polymorphic sites at
positions 51, 59, 108 and 164 was unsuccessful, due pri-
marily to severe fragmentation of the templates extracted
from the methanol-fixed blood smears, which were not
suitable for amplification of fragments greater than 200-
base pairs [24,25]. Thus, three 190-base pair fragments
covering the polymorphic amino acid positions at 51 and
59, 108, and 164 were separately amplified by nested PCR
[23]. The PCR products were subjected to direct sequen-
cing in both directions. In samples with mixed infections
of different genotypes showing superimposed peaks on
an electropherogram, the PCR products were cloned into
pT7Blue vector (Merck, Darmstadt, Germany) and
sequenced. More than 10 plasmid clones were sequenced
to ascertain linkage of the polymorphisms at 51 and 59 in
dhfr; those clones in which linkage was not confirmed
were excluded from further analysis. For genotyping of
the pfcrt locus, a 190-base pair fragment of pfcrt encod-
ing the amino acid residues at positions 72-76 was ampli-
fied by nested PCR as previously described [5].
Statistical analysis
Comparisons between the prevalence of drug resistant
genotypes before and after 1995 were examined using the
Fisher exact test or Chi-square analysis. A p-value of less
than 0.05 was considered to be statistically significant.
Results
Pyrimethamine-resistant genotype
Genotyping of dhfr was successful in 59 of the 122
archive samples, of which 37 (63%) showed mixed infec-
tions of different dhfr genotypes (Figures 1a and 2a). In
addition to the wild-type (NCSI), seven mutant genotypes
were identified: three with a single mutation (NRSI, ICSI,
NCNI), three with double mutations (IRSI, ICNI, NRNI),
and one with a triple mutation (IRNI). The most Pyr-
resistant genotype (IRNL) known so far was not found in
the present study. Of note, the three mutant genotypes
lacking the S108N mutation (NRSI, ICSI, IRSI) were
more prevalent before 1994 than after 1995 (p < 0.0001,
Fisher exact test).
The IRNI genotype, which is currently predominant in
many endemic regions in Africa [26], was first identified
in Nigeria in 1991 in the present samples (Figure 2a).
Since then, the frequency of IRNI genotype gradually
increased (Figure 1a), but it was not highly predominant
in both East Africa (16%) and West Africa (18%) in
1991-1998. Instead, the double mutant genotypes (ICNI
and NRNI) were predominant during that period in the
present sample set. The NRNI genotype was identified
exclusively in West African countries: Nigeria, Ghana,
Cote d’Ivoire, and Niger (Figure 2a). On the other hand,
the ICNI genotype was prevalent in both East and West
Africa.
Chloroquine-resistant genotype
Genotyping of pfcrt was successful in 80 of the 122
archive samples. Only two pfcrt genotypes were found;
the wild-type (CVMNK) and the CQ-resistant genotype
(CVIET) of Southeast Asia (Figure 1b). Mixed infections
of wild-type and CVIET type were found in 22 (28%)
samples. The SVMNT pfcrt genotype that originated in
either Melanesia or South America was not detected.
The CVIET genotype was already present as early as
1984 in Tanzania and Nigeria in the present samples
(Figure 2b), and appeared throughout the studied period
(1984-1998). There was no difference in the prevalence
of the CQ-resistant pfcrt genotype (CVIET) before 1994
and after 1995 (p > 0.8, Chi-square analysis). The preva-
lence of CQ-resistant pfcrt genotype between West and
East Africa was comparable (p > 0.48, Chi-square test).
Discussion
The present study is the first to report pfcrt and dhfr
genotypes in Africa before 1990 using archive samples.
It was found that before the mid-1990s the predominant
dhfr genotypes were wild-type (NCSI) and three mutant
genotypes (NRSI, ICSI, IRSI), all of which lacked the
S108N mutation. This is unexpected because it was
believed that the initial mutation in dhfr was exclusively
the S108N mutation, which confers weak resistance to
Pyr on P. falciparum [10-13]. Experimental investiga-
tions have recently demonstrated that mutant genotypes
lacking the S108N mutation (NRSI, ICSI, IRSI) are as
sensitive to Pyr as the wild-type parasite [13,27]. Nota-
bly, the prevalence of these three mutant genotypes
(NRSI, ICSI, IRSI) lacking the S108N mutation, as well
as the wild-type, was remarkably reduced after the mid-
1990s. Instead, dhfr mutant genotypes possessing the
S108N mutation became more frequent in the late
1990s than in the early 1990s. SP had been used as a
secondary treatment for CQ-resistant falciparum malaria
in limited African countries before the mid-1990s [5],
but was widely deployed in many African countries fol-
lowing the first official introduction of SP as the first-
line treatment for uncomplicated malaria in Malawi in
1993. Therefore it seems likely that increased Pyr pres-
sure may have led to the increased prevalence of dhfr
genotypes with the S108N mutation, and the observed
reduction in the three Pyr-sensitive genotypes (NRSI,
ICSI, IRSI) and wild-type (NCSI) in Africa.
This study also showed that the dhfr triple mutant
(IRNI), a highly Pyr-resistant genotype, was already pre-
sent in Central and West Africa in the early 1990s;
Nigeria in 1991, Uganda in 1992, and Mali in 1993. The
earliest appearance of the IRNI genotype, known to
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date, was in 1988 in Kenya [22], and this genotype was
shown to have been introduced from Southeast Asia.
Most of the IRNI genotype currently prevalent in Africa
has been generated from this migrated resistant parasite
lineage [14,18,19,28], which arrived in East Africa then
rapidly moved westwards. Thus, the identification of the
IRNI genotype in Nigeria in 1991 supports the idea that
the Southeast Asian resistant parasite had already
migrated into Central/West Africa in the early 1990s,
during which time treatment with Pyr was not common
in Africa. However, this idea needs to be confirmed
because migration of this type from Southeast Asia can-
not be substantiated without the assessment of microsa-
tellite haplotypes flanking dhfr [18,19]. Indeed, an
indigenous origin of the same triple mutant (IRNI) gen-
otype, having microsatellite haplotypes distinctive from
the Southeast Asian haplotypes, has recently been
shown in Cameroon [29] and Kenya [14,30]. In the pre-
sent study, unfortunately, it was not feasible to deter-
mine the lineage of the resistant parasite with the triple
mutant (IRNI) genotype, as sufficient amounts of DNA
required to determine the microsatellite haplotypes
could not be recovered from the Giemsa-stained thin
blood smears. However, the recently discovered indigen-
ous African parasite lineage was observed in low fre-
quency compared to the Southeast Asian parasite
lineage [14,29]. Hence, it seems likely that the Southeast
Asian parasite lineage had already migrated to Africa
Figure 1 Yearly change in the number of dhfr- and pfcrt-genotypes in Africa between 1984 and 1998. (a) Wild-type (NCSI),
pyrimethamine-sensitive (NRSI, ICSI, IRSI) and pyrimethamine-resistant (NCNI, ICNI, NRNI, IRNI) dhfr genotypes were identified in blood samples
collected from cases of Plasmodium falciparum malaria in Africa between 1984 and 1998. The height of each coloured bar shows the number of
samples in that year infected with that particular genotype. (b) Wild-type (CVMNK; white bars) and chloroquine-resistant (CVIET; black bars) pfcrt
genotypes were identified in blood samples collected as above. The height of each bar shows the number of samples in that year infected with
that genotype.
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Figure 2 Time-line scheme for dhfr and pfcrt genotypes determined using samples from Africa between 1984 and 1998. (a) Wild-type
(NCSI), pyrimethamine-sensitive (NRSI, ICSI, IRSI) and pyrimethamine-resistant (NCNI, ICNI, NRNI, IRNI) dhfr genotypes of Plasmodium falciparum
are shown by the different coloured symbols, as listed at the bottom of the figure. In samples with mixed genotype infections, the different
genotypes are listed together and underlined. Values in parentheses are the number of samples. *One individual that returned from Ghana in
1993 also visited Burkina Faso in the same trip. (b) Wild-type (CVMNK) and chloroquine-resistant (CVIET) pfcrt genotypes of P. falciparum are
shown by white and black circles, respectively. In samples with mixed genotype infections, the different genotypes are listed together and
underlined. Values in parentheses are the number of samples. *One individual returning from Ghana in 1993 and one individual returning from
Togo in 1990 also visited Burkina Faso in the same trip.
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before SP was widely used in Africa, and subsequently
spread across the continent after the increased use of
SP.
The highest Pyr-resistant dhfr genotype, quadruple
mutant (IRNL), was not identified in the present sample
set. Consistently, the earliest record of the appearance of
IRNL genotype in Africa was in 1999 from Uganda [31]-
in 2000 from Tanzania [32]. However, the prevalence of
the IRNL genotype is notably still low in many endemic
countries in Africa [30] in spite of the intense usage of
SP as a first-line therapy [33]. This is in sharp contrast to
a high prevalence of the IRNL genotype in Indochina,
where the genotype has remarkably increased after the
initial identification in the late 1980s [33,34]. Many fac-
tors appear to be associated with the observed difference
of the prevalence of the IRNL genotype between Africa
and Indochina. One factor could be a level of acquired
immunity against falciparum malaria. In many endemic
areas in Africa, adults acquire semi-immunity after
repeated infections. In those individuals SP is considered
to be effective to not only Pyr-sensitive parasites but also
Pyr-resistant parasites. Importantly, the IRNL genotype is
reportedly not associated with SP treatment failure or in
vivo resistance in individuals who have high levels of
immunity to malaria [33,35]. It is thus suggested that the
IRNL genotype has not been strongly selected for by SP
pressure in semi-immune African adults, and conse-
quently the genotype has not expanded in Africa. Other
factors that have retarded the expansion of the IRNL
genotype in Africa cannot be excluded, and this issue
needs to be clarified in the near future.
This study is the first to report the occurrence of the
CVIET CQ-resistant pfcrt genotype as early as 1984 in
Nigeria. Previously, the oldest identification of the pfcrt
mutant genotype was in 1989 in East Africa [21] and in
1992 in West Africa [36]. This strongly suggests that
CQ resistance, which first arrived in East Africa from
Southeast Asia, had already spread to West Africa by
1984. Around that time, however, CQ efficacy was satis-
factory in the countries of western Africa, and several in
vivo tolerance and resistance cases were reported only
in non-immune individuals [37-39]. Acquired immunity
against malaria in individuals in highly endemic areas in
Africa may have strengthened the efficacy of CQ against
the CQ-resistant parasites [6,7] and probably masked
the appearance of clinical CQ resistance.
In contrast to the mainland of Africa, where resistance
to CQ and Pyr is widely spread, CQ and Pyr are still
effective in Madagascar and Comoros in the south-wes-
tern Indian Ocean [40]. A recent report has shown that
Pyr resistant genotypes found in Madagascar were intro-
duced from Comoros [41]. Unfortunately, the present
sample set included only one sample from Madagascar,
and thus it is difficult to infer when and from where
drug resistant genotype was introduced to Madagascar
and Comoros islands. Further molecular surveys of sam-
ples from African countries including Madagascar and
Comoros are required for better understanding of the
evolutionary history of drug resistance in the continent.
Conclusions
The present study used archive blood samples to reveal
new aspects of the evolutionary history of Plasmodium
falciparum resistance to Pyr and CQ in Africa. Pyr-sen-
sitive mutant genotypes lacking the S108N mutation
were frequently observed in the 1980s but were drasti-
cally reduced in the late 1990s, and instead, the fre-
quency of highly Pyr-resistant genotypes (double and
triple mutants) considerably increased after the mid-
1990s. In addition, the CQ-resistant pfcrt genotype,
CVIET, was identified as early as 1984 in West Africa.
Further molecular epidemiological investigations using
archive samples from diverse endemic areas would lead
to a better understanding of the evolutionary history of
drug resistance of P. falciparum.
Additional material
Additional file 1: Table S1. Plasmodium falciparum pfcrt and dhfr
genotypes determined in 85 blood smears from Africa between
1984 and 1998. Footnotes: The pfcrt and dhfr genotypes determined
are shown for each individual sample. Mutated amino acid residues are
underlined. pfcrt, P. falciparum chloroquine-resistance transporter; dhfr,
dihydrofolate reductase; nd, not determined.
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